Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study.
J Eur Acad Dermatol Venereol
; 28(8): 1127-9, 2014 Aug.
Article
en En
| MEDLINE
| ID: mdl-24330415
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Psoriasis
/
Pie
/
Mano
/
Anticuerpos Monoclonales
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
Límite:
Humans
Idioma:
En
Año:
2014
Tipo del documento:
Article